135 related articles for article (PubMed ID: 33613843)
1. High mRNA expression of LY6 gene family is associated with overall survival outcome in pancreatic ductal adenocarcinoma.
Russ E; Bhuvaneshwar K; Wang G; Jin B; Gage MM; Madhavan S; Gusev Y; Upadhyay G
Oncotarget; 2021 Feb; 12(3):145-159. PubMed ID: 33613843
[TBL] [Abstract][Full Text] [Related]
2. Human
Rathbun LA; Magliocco AM; Bamezai AK
Oncotarget; 2023 May; 14():426-437. PubMed ID: 37141412
[TBL] [Abstract][Full Text] [Related]
3. Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome.
Luo L; McGarvey P; Madhavan S; Kumar R; Gusev Y; Upadhyay G
Oncotarget; 2016 Mar; 7(10):11165-93. PubMed ID: 26862846
[TBL] [Abstract][Full Text] [Related]
4. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.
Qian ZR; Rubinson DA; Nowak JA; Morales-Oyarvide V; Dunne RF; Kozak MM; Welch MW; Brais LK; Da Silva A; Li T; Li W; Masuda A; Yang J; Shi Y; Gu M; Masugi Y; Bui J; Zellers CL; Yuan C; Babic A; Khalaf N; Aguirre A; Ng K; Miksad RA; Bullock AJ; Chang DT; Tseng JF; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar M; Wollison B; Laing A; Hahn WC; Meyerson M; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Wolpin BM
JAMA Oncol; 2018 Mar; 4(3):e173420. PubMed ID: 29098284
[TBL] [Abstract][Full Text] [Related]
5. Potential Prognostic Biomarkers of OSBPL Family Genes in Patients with Pancreatic Ductal Adenocarcinoma.
Chou CW; Hsieh YH; Ku SC; Shen WJ; Anuraga G; Khoa Ta HD; Lee KH; Lee YC; Lin CH; Wang CY; Wang WJ
Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829830
[TBL] [Abstract][Full Text] [Related]
6. LY6 gene family presents a novel class of potential biomarkers associated with overall survival outcome of pancreatic ductal adenocarcinoma.
Gravekamp C
Oncotarget; 2021 Jun; 12(12):1122-1123. PubMed ID: 34136080
[No Abstract] [Full Text] [Related]
7. Bioinformatics analysis of the transcriptional expression of minichromosome maintenance proteins as potential indicators of survival in patients with cervical cancer.
Wu B; Xi S
BMC Cancer; 2021 Aug; 21(1):928. PubMed ID: 34404366
[TBL] [Abstract][Full Text] [Related]
8. TNFSF9 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Pancreatic Cancer.
Wu J; Wang Y; Jiang Z
J Gastrointest Cancer; 2021 Mar; 52(1):150-159. PubMed ID: 32077004
[TBL] [Abstract][Full Text] [Related]
9. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of E2F Transcription Factor Expression in Pancreatic Adenocarcinoma.
Luo L; Zhang G; Wu T; Wu G
Med Sci Monit; 2021 Nov; 27():e933443. PubMed ID: 34799547
[TBL] [Abstract][Full Text] [Related]
11. IMUP and GPRC5A: two newly identified risk score indicators in pancreatic ductal adenocarcinoma.
Wei R; Qi G; Zeng Z; Shen N; Wang Z; Shen H; Gao L; Song C; Ma W; Wang C
Cancer Cell Int; 2021 Nov; 21(1):620. PubMed ID: 34819098
[TBL] [Abstract][Full Text] [Related]
12. Emerging Role of Novel Biomarkers of Ly6 Gene Family in Pan Cancer.
Upadhyay G
Adv Exp Med Biol; 2019; 1164():47-61. PubMed ID: 31576539
[TBL] [Abstract][Full Text] [Related]
13. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
14. Bioinformatics and survival analysis of glia maturation factor-γ in pan-cancers.
Lan A; Ren C; Wang X; Tong G; Yang G
BMC Cancer; 2021 Apr; 21(1):423. PubMed ID: 33863293
[TBL] [Abstract][Full Text] [Related]
15. SRPX2 and RAB31 are effective prognostic biomarkers in pancreatic cancer.
Li H; Zhang SR; Xu HX; Wang WQ; Li S; Li TJ; Ni QX; Yu XJ; Liu L; Wu CT
J Cancer; 2019; 10(12):2670-2678. PubMed ID: 31258775
[No Abstract] [Full Text] [Related]
16. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of the correlation between the expression of WFDC2 in B cells of lung adenocarcinoma tissue and the survival rate of patients].
Zhang H; Lu J; Yang Y; Wang L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 May; 35(5):425-433. PubMed ID: 31223112
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Transcriptomic Analysis Reveals the Role of the Immune Checkpoint HLA-G Molecule in Cancers.
Xu HH; Gan J; Xu DP; Li L; Yan WH
Front Immunol; 2021; 12():614773. PubMed ID: 34276642
[TBL] [Abstract][Full Text] [Related]
19. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
20. Expression, Prognosis and Gene Regulation Network of NFAT Transcription Factors in Non-Small Cell Lung Cancer.
Ma J; Du R; Huang Y; Zhong W; Gui H; Mao C; Song X; Lu J
Pathol Oncol Res; 2021; 27():529240. PubMed ID: 34257525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
